Proteomics. 2015 Sep;15(17):2999-3019. doi: 10.1002/pmic.201400611. Epub 2015 Jun 17.
PMID:25959087
Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J, Villanueva JL, Kindelan JM, Jurado R, Sanchez-Guijo P.
Unveiling six potent and highly selective antileishmanial agents via the open source compound collection 'Pathogen Box' against antimony-sensitive and -resistant Leishmania braziliensis.
Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant Leishmania donovani With Increased Efficacy.
Mukherjee S, Pradhan S, Ghosh S, Sundar S, Das S, Mukherjee B, Roy S.
Front Cell Infect Microbiol. 2020 Nov 10;10:595415. doi: 10.3389/fcimb.2020.595415. eCollection 2020.
PMID:33240825
Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compounds.
Falcoff E, Taranto NJ, Remondegui CE, Dedet JP, Canini LM, Ripoll CM, Dimier-David L, Vargas F, Giménez LA, Bernabó JG, et al.
Trans R Soc Trop Med Hyg. 1994 Jan-Feb;88(1):95-7. doi: 10.1016/0035-9203(94)90518-5.
PMID:8154019
Reversible ototoxicity: a rare adverse reaction of liposomal amphotericin-B used for the treatment of antimony-resistant visceral leishmaniasis in an elderly male.
Das P, Kandel R, Sikka K, Dey A.
Clin Med Insights Case Rep. 2014 Jul 24;7:63-6. doi: 10.4137/CCRep.S15111. eCollection 2014.
PMID:25093006
Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B.
Torre-Cisneros J, Prada JL, Villanueva JL, Valverde F, Sánchez-Guijó P.